Connect your AI

MAZE MAZE Operating lease liabilities

Operating lease liabilities at other companies

Septerna, Inc.SEPN

——

Olema Pharmaceuticals, Inc.OLMA

——

MapLight Therapeutics, Inc. MPLT

——

Nurix Therapeutics, Inc.NRIX

——

Zevra Therapeutics, Inc.ZVRA

——

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

Revenue$20.0M—

Operating income-$26.6M+25.0%

Net income-$24.2M+26.2%

EPS (diluted)-$0.45+60.9%

Balance sheet

Cash & equivalents$198.8M-32.5%

Total debt$61.2M+137%

Total equity$341.7M+17.0%

Total assets$419.7M+26.1%

Cash flow

Operating cash flow-$39.1M-32.5%

CapEx$93.0K-68.9%

Free cash flow-$39.2M-31.5%

Valuation

Market cap$1.5B+205%

Enterprise value$1.36B—

P/S8×—

Profitability

Operating margin-71.5%—

Net margin-65.4%—

FCF margin-65.1%—

Returns & leverage

Return on equity-38.7%—

Debt / equity0.2×+0.1×

Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MAZE's operating lease liabilities?: MAZE (MAZE) reported operating lease liabilities of -$915K in Q1 2026.
How has MAZE's operating lease liabilities changed year-over-year?: MAZE's operating lease liabilities decreased by 13.7% year-over-year, from -$805K to -$915K.